Market LIVE
Published markets; coverage varies by country
Product profile · United States

ZYTIGA

 ·  Patent Litigation & Settlement History ↓

IngredientABIRATERONE ACETATE
Application typeNDA
Application202379
Product002
Dosage formTABLET
RouteORAL
Strength500MG
Approval date2017-04-14
Marketing statusPrescription
Status event—
ApplicantJANSSEN BIOTECH
Product source

Current GenericRadar decision

Year2020
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2020-12-14
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2020-12-14
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
208446 / 002FINAL_APPROVAL · FINAL_APPROVED2020-12-14—MYLAN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208327 / 002FINAL_APPROVAL · FINAL_APPROVED2020-12-23—AMNEAL PHARMACEUTICALS OF NEW YORK LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212462 / 002FINAL_APPROVAL · FINAL_APPROVED2021-06-25—QILU PHARMACEUTICAL CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215947 / 002FINAL_APPROVAL · FINAL_APPROVED2022-01-05—NOVUGEN ONCOLOGY SDN BHDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209227 / 002FINAL_APPROVAL · FINAL_APPROVED2022-05-19—GLENMARK SPECIALTY SANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210726 / 001FINAL_APPROVAL · FINAL_APPROVED2023-01-26—TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215086 / 001FINAL_APPROVAL · FINAL_APPROVED2023-03-23—FLORIDA PHARMACEUTICAL PRODUCTS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208416 / 002FINAL_APPROVAL · FINAL_APPROVED2023-09-01—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210686 / 002FINAL_APPROVAL · FINAL_APPROVED2024-04-24—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 9 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
208446 / 002MYLAN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2020-12-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208327 / 002AMNEAL PHARMACEUTICALS OF NEW YORK LLCFINAL_APPROVAL · FINAL_APPROVED2020-12-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212462 / 002QILU PHARMACEUTICAL CO LTDFINAL_APPROVAL · FINAL_APPROVED2021-06-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215947 / 002NOVUGEN ONCOLOGY SDN BHDFINAL_APPROVAL · FINAL_APPROVED2022-01-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209227 / 002GLENMARK SPECIALTY SAFINAL_APPROVAL · FINAL_APPROVED2022-05-19 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210726 / 001TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2023-01-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215086 / 001FLORIDA PHARMACEUTICAL PRODUCTS LLCFINAL_APPROVAL · FINAL_APPROVED2023-03-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208416 / 002DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2023-09-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210686 / 002MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2024-04-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2020-12-14TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.